NCT04165330 2025-02-24Evaluation of AL3818 in Combination With Nivolumab in Solid TumorsSarcoma Oncology Research Center, LLCPhase 1/2 Active not recruiting56 enrolled
NCT05400070 2024-10-18Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLCTang-Du HospitalPhase 2 Active not recruiting45 enrolled